Home / Business and Economy / Whoop Taps Former FDA Chair Amid Regulatory Scrutiny
Whoop Taps Former FDA Chair Amid Regulatory Scrutiny
22 Jul
Summary
- Whoop appointed Dr. Ami Bhatt as its new Chief Medical Officer.
- Dr. Bhatt previously chaired a US Food and Drug Administration committee.
- The appointment follows a recent disagreement between Whoop and the FDA.
Whoop Inc., the company behind popular screenless fitness trackers, has appointed Dr. Ami Bhatt to serve as its next Chief Medical Officer. This significant leadership change follows a recent period of contention between the wearable technology firm and the U.S. Food and Drug Administration.
Dr. Bhatt brings a wealth of experience to her new role. She is a board-certified cardiologist and notably served as the inaugural chair of a prominent committee within the US Food and Drug Administration. Her appointment signals a potential shift in how Whoop engages with regulatory frameworks.
The transition to a former FDA committee chair into a key executive position at Whoop may indicate the company's intention to proactively address and navigate regulatory landscapes. This move could enhance their strategic approach to product development and compliance.
